239 related articles for article (PubMed ID: 29677220)
1. HIV-1 adaptation studies reveal a novel Env-mediated homeostasis mechanism for evading lethal hypermutation by APOBEC3G.
Ikeda T; Symeonides M; Albin JS; Li M; Thali M; Harris RS
PLoS Pathog; 2018 Apr; 14(4):e1007010. PubMed ID: 29677220
[TBL] [Abstract][Full Text] [Related]
2. HIV-1 restriction by endogenous APOBEC3G in the myeloid cell line THP-1.
Ikeda T; Molan AM; Jarvis MC; Carpenter MA; Salamango DJ; Brown WL; Harris RS
J Gen Virol; 2019 Jul; 100(7):1140-1152. PubMed ID: 31145054
[TBL] [Abstract][Full Text] [Related]
3. Mechanism of Enhanced HIV Restriction by Virion Coencapsidated Cytidine Deaminases APOBEC3F and APOBEC3G.
Ara A; Love RP; Follack TB; Ahmed KA; Adolph MB; Chelico L
J Virol; 2017 Feb; 91(3):. PubMed ID: 27881650
[TBL] [Abstract][Full Text] [Related]
4. Long-term passage of Vif-null HIV-1 in CD4
Miyagi E; Kao S; Fumitaka M; Buckler-White A; Plishka R; Strebel K
Virology; 2017 Apr; 504():1-11. PubMed ID: 28131088
[TBL] [Abstract][Full Text] [Related]
5. Simian Immunodeficiency Virus Vif and Human APOBEC3B Interactions Resemble Those between HIV-1 Vif and Human APOBEC3G.
Wang J; Shaban NM; Land AM; Brown WL; Harris RS
J Virol; 2018 Jun; 92(12):. PubMed ID: 29618650
[TBL] [Abstract][Full Text] [Related]
6. [Advances in the study of molecular mechanism of APOBEC3G anti-HIV-1].
Fan B; Cen S; Jiang JD
Yao Xue Xue Bao; 2008 Jul; 43(7):678-82. PubMed ID: 18819469
[TBL] [Abstract][Full Text] [Related]
7. Functional and Structural Insights into a Vif/PPP2R5 Complex Elucidated Using Patient HIV-1 Isolates and Computational Modeling.
Salamango DJ; McCann JL; Demir Ö; Becker JT; Wang J; Lingappa JR; Temiz NA; Brown WL; Amaro RE; Harris RS
J Virol; 2020 Oct; 94(21):. PubMed ID: 32847850
[TBL] [Abstract][Full Text] [Related]
8. Polymorphisms in the APOBEC3G gene of Chinese rhesus macaques affect resistance to ubiquitination and degradation mediated by HIV-2 Vif.
Jiang ZQ; Yao XR; Yu H; Lu YE; Liu BL; Liu FL; Jin YB; Zhuo M; Zheng YT; Ling F
Arch Virol; 2019 May; 164(5):1353-1360. PubMed ID: 30859472
[TBL] [Abstract][Full Text] [Related]
9. Endogenous origins of HIV-1 G-to-A hypermutation and restriction in the nonpermissive T cell line CEM2n.
Refsland EW; Hultquist JF; Harris RS
PLoS Pathog; 2012; 8(7):e1002800. PubMed ID: 22807680
[TBL] [Abstract][Full Text] [Related]
10. Evolution of HIV-1 isolates that use a novel Vif-independent mechanism to resist restriction by human APOBEC3G.
Haché G; Shindo K; Albin JS; Harris RS
Curr Biol; 2008 Jun; 18(11):819-24. PubMed ID: 18501607
[TBL] [Abstract][Full Text] [Related]
11. HIV-1 viral infectivity factor (Vif) alters processive single-stranded DNA scanning of the retroviral restriction factor APOBEC3G.
Feng Y; Love RP; Chelico L
J Biol Chem; 2013 Mar; 288(9):6083-94. PubMed ID: 23316055
[TBL] [Abstract][Full Text] [Related]
12. Anti-APOBEC3G activity of HIV-1 Vif protein is attenuated in elite controllers.
Kikuchi T; Iwabu Y; Tada T; Kawana-Tachikawa A; Koga M; Hosoya N; Nomura S; Brumme ZL; Jessen H; Pereyra F; Trocha A; Walker BD; Iwamoto A; Tokunaga K; Miura T
J Virol; 2015 May; 89(9):4992-5001. PubMed ID: 25717111
[TBL] [Abstract][Full Text] [Related]
13. Host AKT-mediated phosphorylation of HIV-1 accessory protein Vif potentiates infectivity via enhanced degradation of the restriction factor APOBEC3G.
Raja R; Wang C; Mishra R; Das A; Ali A; Banerjea AC
J Biol Chem; 2022 Apr; 298(4):101805. PubMed ID: 35259395
[TBL] [Abstract][Full Text] [Related]
14. Vif hijacks CBF-β to degrade APOBEC3G and promote HIV-1 infection.
Jäger S; Kim DY; Hultquist JF; Shindo K; LaRue RS; Kwon E; Li M; Anderson BD; Yen L; Stanley D; Mahon C; Kane J; Franks-Skiba K; Cimermancic P; Burlingame A; Sali A; Craik CS; Harris RS; Gross JD; Krogan NJ
Nature; 2011 Dec; 481(7381):371-5. PubMed ID: 22190037
[TBL] [Abstract][Full Text] [Related]
15. An analog of camptothecin inactive against Topoisomerase I is broadly neutralizing of HIV-1 through inhibition of Vif-dependent APOBEC3G degradation.
Bennett RP; Stewart RA; Hogan PA; Ptak RG; Mankowski MK; Hartman TL; Buckheit RW; Snyder BA; Salter JD; Morales GA; Smith HC
Antiviral Res; 2016 Dec; 136():51-59. PubMed ID: 27825797
[TBL] [Abstract][Full Text] [Related]
16. A naturally occurring Vif mutant (I107T) attenuates anti-APOBEC3G activity and HIV-1 replication.
Peng J; Ao Z; Matthews C; Wang X; Ramdahin S; Chen X; Li J; Chen L; He J; Ball B; Fowke K; Plummer F; Embree J; Yao X
J Mol Biol; 2013 Aug; 425(16):2840-52. PubMed ID: 23707381
[TBL] [Abstract][Full Text] [Related]
17. The Disassociation of A3G-Related HIV-1 cDNA G-to-A Hypermutation to Viral Infectivity.
Martin J; Chen X; Jia X; Shao Q; Liu B
Viruses; 2024 May; 16(5):. PubMed ID: 38793610
[TBL] [Abstract][Full Text] [Related]
18. Tumultuous relationship between the human immunodeficiency virus type 1 viral infectivity factor (Vif) and the human APOBEC-3G and APOBEC-3F restriction factors.
Henriet S; Mercenne G; Bernacchi S; Paillart JC; Marquet R
Microbiol Mol Biol Rev; 2009 Jun; 73(2):211-32. PubMed ID: 19487726
[TBL] [Abstract][Full Text] [Related]
19. Identification of small molecule compounds targeting the interaction of HIV-1 Vif and human APOBEC3G by virtual screening and biological evaluation.
Ma L; Zhang Z; Liu Z; Pan Q; Wang J; Li X; Guo F; Liang C; Hu L; Zhou J; Cen S
Sci Rep; 2018 May; 8(1):8067. PubMed ID: 29795228
[TBL] [Abstract][Full Text] [Related]
20. HIV-1 Vif Gained Breadth in APOBEC3G Specificity after Cross-Species Transmission of Its Precursors.
Chesarino NM; Emerman M
J Virol; 2022 Feb; 96(4):e0207121. PubMed ID: 34908448
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
